Carbidopa for the Treatment of Excessive Blood Pressure Variability

Completed · Phase 2 · Has a placebo group

Conditions studied: Dysautonomia, Familial, Baroreflex Failure Syndrome

In brief

The overall study objectives are to determine whether carbidopa (Lodosyn®) is safe and well tolerated and to assess whether it can inhibit catecholamine-induced paroxysmal hypertension and normalize or reduce the exaggerated blood pressure variability in patients with familial dysautonomia (FD, also called hereditary sensory and autonomic neuropathy type III or Riley-Day syndrome). Funding Source- FDA OOPD.

Key facts

Study ID
NCT02553265
Run by
NYU Langone Health
People needed
22
Starts
2015-09-01
Expected to finish
2019-05-10
Last updated by the study team
2022-02-09

Who can join

Age: 10 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.